Decision Resources Release: The Breast Cancer Drug Market Will Increase Marginally over the Next Decade, Despite Generic and Biosimilar Erosion of Key Agents

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the breast cancer therapy market will decline to $9.3 billion in 2011 before rising to $10.6 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

MORE ON THIS TOPIC